Tagged with A

AstraZeneca Hungary The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in Hungary? I would say that it has become an extremely difficult environment to operate in. There is a myth that…

Janssen Pharmaceutical Hungary Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag within the CEE region today? It is not the easiest question, as Hungary’s importance is changing from year to year.…

Cegedim Hungary Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other pharmaceutical markets in the region? I think key particularities are the many legal constraints. In July 2011, the law changed…

Boehringer Ingelheim Hungary Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right after the fall of the Iron Curtain… Can you provide our readers with a better idea of the role that…

Sanofi-Aventis Hungary Sanofi for 3,5 years. It must have been quite a different market, culture and environment. Yet, at that time you publicly announced that it only took you 30 seconds to accept the move. Why was this such an easy choice? In Hungary, Sanofi has a presence that reaches far beyond…

BOIRON Hungary Hungary has one of the oldest drug industries in Europe, but homeopathy too has quite a history in the country, with the Homoeopathic Doctor’s Association being founded as early as 1864. Do you feel that –today- homeopathy has taken its rightful position within the Hungarian healthcare system? First of all,…

Russia CONSULTING You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind the creation of Russia Consulting, and the main growth drivers contributing to its development? When I was a student, I…

Quintiles Russia The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in Russia, after setting up a local legal entity for the delivery of commercial operations. What is the nature of this…

Quintiles Russia The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of its first commercial project in Russia, after setting up a local legal entity for the delivery of commercial operations. What…

EGIS Romania You have been general manager of this affiliate for three years after a previous tenure as general manager of Leo Pharma here and in Bulgaria. The end of 2008 through 2010 were certainly not the easiest years for pharmaceutical companies. What was the business environment like when you first came…

GSK Pharma CIS GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s portfolio into novel areas and putting greater emphasis on emerging markets. How is the Russian affiliate contributing to the realization…

Invar The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in Russia immediately after the fall of the Soviet Union. This company began as a regional investment & consulting business—why did…